Immatics/$IMTX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Immatics

Immatics NV is a biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.

Ticker

$IMTX
Sector
Primary listing

Employees

618

Immatics Metrics

BasicAdvanced
$707M
-
-$0.76
1.02
-

What the Analysts think about Immatics

Analyst ratings (Buy, Hold, Sell) for Immatics stock.

Bulls say / Bears say

Immatics moved from a net loss of €94.6 million in 2023 to a net profit of €15.2 million in FY 2024, driven by one-time collaboration revenue and showing improved financial resilience (Reuters)
The company increased its cash reserves to €604.5 million as of December 31, 2024, extending its financial runway into the second half of 2027 to support ongoing R&D efforts (Reuters)
Immatics started enrolling patients in its pivotal SUPRAME Phase 3 trial for IMA203 in previously treated advanced melanoma, a key milestone toward a possible regulatory filing in 2027 (Reuters)
Revenue dropped 74.7% year-over-year to €4.74 million in Q2 2025, falling well short of analysts' consensus forecast of €13.81 million (Reuters)
Immatics posted an adjusted loss of €0.58 per share in Q2 2025, compared with the expected €-0.32, widening from a loss of €0.17 a year earlier and highlighting growing losses in clinical-stage operations (Reuters)
Q1 2025 revenue fell 38.6% year-over-year to €18.58 million, missing forecasts and showing instability in collaboration-derived revenue (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.

Immatics Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Immatics Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IMTX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs
Buy Immatics stock | $IMTX Share Price | Lightyear